PASGPassage Bio, Inc.

$29M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$15M

EPS (Diluted)

$-4.96

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$858,000

Balance Sheet

Total Assets

$86M

Total Liabilities

$39M

Stockholders' Equity

$47M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$18M	+8.8%
Net Income	-$15M	-$17M	+7.8%

PASG Q1 2025 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena